

PERSONAL INFORMATION

Niccolò Bolli
Born in Perugia on January 3rd 1977
Italian Nationality

CURRENT POSITIONS

Associate Professor of Hematology at University of Milan
Consultant in Hematology at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

WORK EXPERIENCE

- 2020-Present** **Associate Professor of Hematology and Consultant in Hematology**
University of Milan - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Research activity on genomics of hematological malignancies, particularly multiple myeloma and myeloid malignancies.
 - Study of mutations responsible for disease pathogenesis and evolution both in pre-clinical phases and after treatment.
 - Application of recent acquisitions on genomics of hematological malignancies for classification and prognostic purposes.
 - Development of diagnostic tests based on next-generation sequencing and other second-generation molecular techniques.
 - Clinical activity for inpatients and outpatients within the neoplastic hematology service
- Business or sector:** Academia/Hospital
- 2015-2020** **Associate Professor of Hematology and Consultant in Hematology**
University of Milan - Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano
- Business or sector:** Academia/Hospital
- 2011-2015** **Academic Clinical Lecturer/Honorary Clinical Fellow in Hematology**
University of Cambridge - Addenbrooke's Hospital, Cambridge, UK
- Research activity on genomics of hematological malignancies, particularly multiple myeloma and myeloid malignancies.
 - Whole exome sequencing of single and paired samples of multiple myeloma to show significant mutations at diagnosis and Study of mutations responsible for disease pathogenesis and evolution both in pre-clinical phases and after treatment.
 - In vitro and in vivo functional validation of RNA splicing gene mutations in myelodysplastic syndromes.
 - Clinical activity for inpatient and outpatient neoplastic hematology service
- Business or sector:** Academia/Hospital
- 2007-2011** **Post-doctoral fellow**
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
- Research activity on biology and genetics of myeloid malignancies.
 - Creation of transient and stable zebrafish models of NPMc+ AML
 - Forward genetic screens in zebrafish to identify genes required for maintenance of definitive hematopoiesis
 - Use of high-resolution SNP arrays to identify genes disrupted in human myelodysplastic syndromes
- Business or sector:** Academia/Hospital
- 2001-2007** **Trainee in hematology and then PhD student**
University of Perugia, Italy
- Research activity on biology and genetics of myeloid malignancies.
 - study of mechanisms of altered NPMc+ subcellular transport in

- human acute myeloid leukemia (AML)
 - study and validation of new diagnostic techniques for NPMc+ AML.
 - Study of the cell of origin of NPMc+ AML
 - Clinical activity for inpatients and outpatients within the neoplastic hematology service

Business or sector: Academia/Hospital

EDUCATION AND TRAINING

- 2019 Italian National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale, Settore concorsuale 06/D3, abilitato come professore di I fascia)
Ministry of education and scientific research
- 2013 Italian National Academic Qualification as Associate Professor (Abilitazione Scientifica Nazionale, Settore concorsuale 06/D3, abilitato come professore di II fascia)
Ministry of education and scientific research
- 2005-2010 Ph. D.
University of Perugia
- 2001-2005 Board certified in Hematology
University of Perugia
- 1995-2001 M.D.
University of Perugia
110/110 cum laude

PERSONAL SKILLS

Mother tongue Italian

Other languages	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
French	B1	B1	A2	A2	A1

[Common European Framework of Reference for Languages](#)

Communication skills I have excellent communication skills that I have acquired during my career as associate professor and lecturer at national and international meetings.

Organisational / managerial skills **Teaching**

- 2019-present: member of the teaching committee of the "International Medical School" of the University of Milan.
- 2019: Organizer of the course "Next generation sequencing in cancer and beyond" for PhD students in translational medicine of the XXXIV cycle of the University of Milan.
- 2018: Lecturer within the course "bioinformatica, biologia computazionale e biostatistica nella medicina molecolare" of the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Riferimento CPD 18 INT – 129342.1).
- 2018-2019: Member of the PhD committee of the XXXIV and XXXV cycle of the PhD program in translational medicine of the University of Milan.

2015-Present: Associate Professor of Hematology at the University of Milan “Statale”, with 120 hours/year of teaching, tutoring and clinical-practical activities in hematology and molecular biology to:

- Students (Medical school, International medical school, Biotechnologies and Medical biotechnologies, post-graduate courses in hematology, oncology and pediatrics)
- PhD Students in Experimental hematology
- Hematology trainees

Responsible for the integrated course “System diseases II” of the International Medical School, University of Milan

Responsible for the integrated course “Scienze Cliniche” of the degree in Dental Hygiene, University of Milan

2012-2013 Instructor at the Wellcome Trust Advanced Course (Hinxton, UK): “Molecular Pathology and Diagnosis of Cancer”.

2011-2015 Clinical Lecturer in Hematology at the University of Cambridge, involved in lecturing and tutoring students of the Cambridge Medical School. Specifically, lecturer in the “Pathology of malignant haematology 1 and 2 courses.

Experience in student examination, supervision and mentoring

2015-Present: As an associate professor of hematology at the University of Milan I have served as an external examiner for 3 PhD students of the Open University (UK), 1 student from the Leuven University (BE), 1 student from University San Raffaele (IT), 1 student from University of Turin (IT), 1 student from University of Padova (IT). I currently am supervisor of 2 PhD students, one from university San Raffaele and one from University of Hasselt (BE).

2015-Present: As an associate professor of hematology at the University of Milan I have been supervising students of the medical school, students in life sciences and hematology trainees. I have personally supervised 5 students to their medical degree, and 2 hematology trainees to their board certification.

2013-2015 As a clinical lecturer at the University of Cambridge I have been supervising PhD students (2), as well as MPhil (1) and MSc (1) students.

Editorial and reviewing activities

Reviewer: Blood, Leukemia, Haematologica, BMC genomics, Oncotarget, Blood Advances, Cancer Research, Nature Communications, Trends in Cancer, Bioinformatics, Journal of Immunology Research, Science Advances, Molecular and Cell Therapy.

2019-2020: Guest editor of the issue on “tumor microenvironment” of Frontiers in Oncology.

2014-2020 Associate Editor of the Onco-hematology section of Tumori Journal

2014-present Reviewer for international grant applications promoted by the Wellcome Trust, the Lady Tata Memorial Trust, the Key Kendall Leukemia Foundation, the Institute National du Cancer, the EEA Research Programme 2014-2021, the Research Foundation, Flanders (FWO), the European

Hematology Association (EHA), the Italian Society of Experimental Hematology (SIES), the Austrian Science Fund.

Honorary Positions

2021-2023:	Member of the Research Foundation, Flanders (FWO) Review College
2021-present	Board Member of the Grants and Fellowship Committee of the European Hematology Association (EHA)
2018-present	Counsellor of the Italian Society of Experimental Hematology (SIES)
2018-present	Member of the European Myeloma Network (EMN)
2018-2020	Member of the commission for biological studies in multiple myeloma of the national group of adult hematological diseases (GIMEMA)
2016-2020	Member of the advisory board for the Scientific Board of the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan
2016-2017	Member of the evaluating commission for post-doctoral applications of the University of Milan
2015-present	Member of the committee for evaluation and implementation of international agreements for the exchange of medical students for internships and summer fellowships of the University of Milan
2014-present	Faculty of the yearly meeting "Under 40 in Hematology – Giovani ematologi a confronto"

Digital skills

SELF ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Proficient User	Proficient User	Proficient User	Proficient User	Proficient User

[Digital competences - Self-assessment grid](#)

Driving licence Type B

ADDITIONAL INFORMATION

Publications

Total citations: 10613. H-index: 36 (Scopus, Aug 2021)

1. Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, et al. Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma Cancers (Basel). 2021 Jun 25;13(13):3189. doi: 10.3390/cancers13133189
2. Rossi M, Meggendorfer M, Zampini M, et al. Clinical relevance of clonal hematopoiesis in the oldest-old population Blood. 2021 Jun 14;blood.2021011320. doi: 10.1182/blood.2021011320
3. Haertle L, Barrio S, Munawar U, et al. Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma Blood. 2021 Jun 11;blood.2020010452. doi: 10.1182/blood.2020010452
4. Holstein SA, Bahlis N, Bergsagel PL, et al. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma Transplant Cell Ther. 2021 Jun 6:S2666-6367(21)00946-5. doi: 10.1016/j.jtct.2021.05.027
5. Bassani B, Tripodo C, Portararo P, et al. CD40 Activity on Mesenchymal

- Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions *Front Immunol.* 2021 May 18;12:662048. doi: 10.3389/fimmu.2021.662048
6. Sacco A, Federico C, Todoerti K, et al. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity *Blood.* 2021 Jun 2;blood.2020010572. doi: 10.1182/blood.2020010572
7. Todoerti K, Ronchetti D, Favasuli V, et al. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome *Haematologica.* 2021 May 6. doi: 10.3324/haematol.2021.278342
8. Rustad EH, Nadeu F, Angelopoulos N, et al. mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies *Commun Biol.* 2021 Mar 29;4(1):424. doi: 10.1038/s42003-021-01938-0
9. Oben B, Froyen G, Maclachlan KH, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities *Nat Commun.* 2021 Mar 25;12(1):1861. doi: 10.1038/s41467-021-22140-0
10. Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes *J Clin Oncol.* 2021 Apr 10;39(11):1223-1233. doi: 10.1200/JCO.20.01659.
11. Bolli N, Sgherza N, Curci P, et al. What Is New in the Treatment of Smoldering Multiple Myeloma? *J Clin Med.* 2021 Jan 22;10(3):421
12. Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. *Hematol Rep.* 2020;12(3).
13. Da Vià MC, Ziccheddu B, Maeda A, et al. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. *HemaSphere.* 2020;4(6):e502.
14. Vittoria, L, Bozzi F, Capone I, Carniti C, Lorenzini D, Gobbo M, Bolli N, and Aiello A. "A Rare Biclinal Hairy Cell Leukemia Disclosed by an Integrated Diagnostic Approach: A Case Report." *Cytometry Part B: Clinical Cytometry* (December 18, 2020). <https://doi.org/10.1002/cyto.b.21980>.
15. Maura F, Doderio A, Carniti C, et al. CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL- NOS). *Haematologica.* <https://doi.org/10.3324/haematol.2020.262659> [Early view]
16. Rustad, Even H, Venkata D Yellapantula, Dominik Glodzik, Kylee H. et al. Revealing the Impact of Structural Variants in Multiple Myeloma. *Blood Cancer Discovery*, 2020.
17. Monti, Valentina, Filippo Bagnoli, Niccolò Bolli, Laura Vittoria, Sabine Stioui, Maria Luisa Moiraghi, et al. A New Case of Myelodysplastic Syndrome Associated with t(3;3)(q21;q26) and Inv(11)(p15q22). *Tumori Journal*, August 24, 2020.
18. Manzoni, Martina, Alessandra Pompa, Sonia Fabris, Francesca Pelizzoni, Gabriella Ciceri, Manuela Seia, Bachisio Ziccheddu, et al. Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. *HemaSphere* 4, no. 4 (August 2020).
19. Manzoni, Martina, Valentina Marchica, Paola Storti, Bachisio Ziccheddu, Gabriella Sammarelli, Giannalisa Todaro, et al. Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. *Cancers* 12, no. 5 (May 23, 2020): 1332.
20. D'Agostino, Mattia, Gian Maria Zaccaria, Bachisio Ziccheddu, Even H Rustad, Elisa Genuardi, Andrea Capra, Stefania Oliva, et al. Early Relapse Risk in Newly Diagnosed Multiple Myeloma Patients Characterized by Next-Generation Sequencing. *Clinical Cancer*

Research, July 2, 2020.

21. Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Lederger G, Nadeu F et al. Timing the initiation of multiple myeloma. *Nat Commun* 2020;11:1917
22. Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? *Front Oncol* 2020;10:189
23. Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. *Blood Adv* 2020;4:830-844
24. Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, Demeulemeester J et al. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition *Nat Genet* 2020;52:306-319
25. Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. *JAMA Oncol.* 2019.
26. Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. *Blood Cancer J. Nature Publishing Group*; 2019;9:101–9.
27. Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. *Nature Communications.* 2019;10:3835.
28. Rustad EH, Yellapantula V, Bolli N, Leongamornlert D, Nadeu F, Angelopoulos N et al. Timing the Initiation of Multiple Myeloma. *SSRN Journal [Internet]*. 2019. Available from: <https://ssrn.com/abstract=3409453>
29. Maura F, Degasper A, Nadeu F, Leongamornlert D, Davies H, Moore L et al. A practical guide for mutational signature analysis in hematological malignancies. *Nature Communications.* Nature Publishing Group; 2019;10:2969.
30. Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan J, Dodero A et al. Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma. *Am J Hematol.* 2019.
31. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. *Leukemia.* 2019;33:159–70.
32. Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A et al. Genomic patterns of progression in smoldering multiple myeloma. *Nature Communications.* 2018;9:3363.
33. Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M et al. Multiple myeloma clonal evolution in homogeneously treated patients. *Leukemia.* Nature Publishing Group; 2018;364:1046.
34. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. *Blood.* American Society of Hematology; 2018;:blood–2018–03–840132–24.
35. Collord G, Martincorena I, Young MD, Feroni L, Bolli N, Stratton MR et al. Recurrent histone mutations in T-cell acute lymphoblastic leukaemia. *Br J Haematol.* 2018.
36. Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. *Leukemia.* 2018;32:1044–8.
37. Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, De Philippis C et al. Analysis of the genomic landscape of multiple myeloma highlights novel

- prognostic markers and disease subgroups. *Leukemia*. 2018;32:2604–16.
38. Soldarini M, Farina L, Genderini A, Bolli N. A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome. *BMJ Case Rep*. BMJ Publishing Group Ltd; 2017;2017:bcr-2016-218850.
 39. Bolli N, Barcella M, Salvi E, D'Avila F, Vendramin A, De Philippis C et al. Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. *Cancer*. 2017;123:3701–8.
 40. Maura F, Guidetti A, Pellegrinelli A, Doderò A, Pennisi M, Caprioli C et al. High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. *Blood Cancer J*. 2016;6:e491.
 41. Wang M, Zhang S, Chuang S-S, Ashton-Key M, Ochoa E, Bolli N et al. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. *Oncotarget*. 2017;8:17763–70.
 42. Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. *Nat Genet*. 2017;49:332–40.
 43. Mupo A, Seiler M, Sathiaselalan V, Pance A, Yang Y, Agrawal AA et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. *Leukemia*. 2016;31:720–7.
 44. Bolli N, Li Y, Sathiaselalan V, Raine K, Jones D, Ganly P et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. *Blood Cancer J*. 2016;6:e467.
 45. De Philippis C, Di Chio MC, Sabattini E, Bolli N. Bowel perforation from occult ileal involvement after diagnosis in a case of primary mediastinal large B-cell lymphoma. *BMJ Case Rep*. 2016;2016.
 46. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N Engl J Med*. 2016;374:2209–21.
 47. McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JML, Tischler G et al. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. *Blood*. 2016;128:e1–9.
 48. Grove CS, Bolli N, Manes N, Varela I, Van't Veer M, Bench A et al. Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution. *Br J Haematol*. 2017;176:825–9.
 49. Maura F, Doderò A, Carniti C, Bolli N. Biology of peripheral T cell lymphomas – Not otherwise specified: Is something finally happening? *Pathogenesis*. Elsevier; 2016;3:9–18.
 50. Bolli N, Manes N, McKerrell T, Chi J, Park N, Gundem G et al. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. *Haematologica*. 2015;100:214–22.
 51. Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai Y-T et al. Differential and limited expression of mutant alleles in multiple myeloma. *Blood*. 2014;124:3110–7.
 52. Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. *Leukemia*. 2015;29:1177–85.
 53. Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. *Elife*. 2014;3.
 54. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M et al. Extensive transduction of nonrepetitive DNA mediated by L1

- retrotransposition in cancer genomes. *Science*. American Association for the Advancement of Science; 2014;345:1251343–3.
55. Sportoletti P, Varasano E, Rossi R, Bereshchenko O, Cecchini D, Gionfriddo I et al. The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. *Blood*. 2013;121:3447–58.
56. Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I, Tubio JMC et al. Processed pseudogenes acquired somatically during cancer development. *Nature Communications*. 2014;5.
57. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. *Nat Genet*. 2014;46:487–91.
58. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nature Communications*. 2014;5:2997.
59. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. *Nature*. 2013;500:415–21.
60. Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. *Leukemia*. 2013;27:1820–5.
61. Payne EM, Bolli N, Rhodes J, Abdel-Wahab OI, Levine R, Hedvat CV et al. Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. *Blood*. 2011;118:903–15.
62. Grabher C, Payne EM, Johnston AB, Bolli N, Lechman E, Dick JE et al. Zebrafish microRNA-126 determines hematopoietic cell fate through c-Myb. *Leukemia*. 2011;25:506–14.
63. Bolli N, Payne EM, Rhodes J, Gjini E, Johnston AB, Guo F et al. cpsf1 is required for definitive HSC survival in zebrafish. *Blood*. 2011;117:3996–4007.
64. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? *Blood*. 2011;117:1109–20.
65. Albiero E, Bolli N, Falini B, De Marco MF, Madeo D, Martelli MP et al. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. *Leukemia*. 2007;21:2052–4; authorreply2054; discussion2055–6.
66. Falini B, Bigerna B, Pucciarini A, Tiacci E, Mecucci C, Morris SW et al. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. *Leukemia*. 2006;20:368–71.
67. Bolli N, Payne EM, Grabher C, Lee J-S, Johnston AB, Falini B et al. Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. *Blood*. 2010;115:3329–40.
68. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. *Leukemia*. 2009;23:1731–43.
69. Liso A, Castiglione F, Cappuccio A, Stracci F, Schlenk RF, Amadori S et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). *Haematologica*. 2008;93:1219–26.
70. Martelli MP, Manes N, Pettrossi V, Liso A, Pacini R, Mannucci R et al. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+

- AML. Leukemia. Nature Publishing Group; 2008;22:195–8.
71. Bolli N, Galimberti S, Martelli MP, Tabarrini A, Roti G, Mecucci C et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. *Lancet Oncol.* 2006;7:350–2.
 72. Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. *Cancer Res. American Association for Cancer Research;* 2007;67:6230–7.
 73. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RAF et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. *Leukemia.* 2005;19:1760–7.
 74. Tiacci E, Orvietani P-L, Bigerna B, Pucciarini A, Corthals GL, Pettrossi V et al. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. *Blood.* 2005;105:2812–20.
 75. Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. *Haematologica.* 2008;93:775–9.
 76. Liso A, Bogliolo A, Freschi V, Martelli MP, Pileri SA, Santodirocco M et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. *Leukemia.* 2008;22:1285–9.
 77. Ballanti S, Mastrodicasa E, Bolli N, Lotti F, Capolsini I, Berchicci L et al. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. *Nat Clin Pract Oncol.* 2007;4:722–5.
 78. Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. *Haematologica.* 2007;92:519–32.
 79. Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. *Leukemia.* 2009;23:501–9.
 80. Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. *Leukemia.* 2007;21:1099–103.
 81. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. *Blood.* 2006;108:1999–2005.
 82. Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. *Haematologica.* 2008;93:1017–24.
 83. Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. *Leukemia.* 2007;21:1566–70.
 84. Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. *Blood.* 2006;108:4146–55.
 85. Martelli MP, Manes N, Liso A, Pettrossi V, Verducci Galletti B, Bigerna B et al. A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. *Leukemia.* 2008;22:2285–8.
 86. Bolli N, Di Ianni M, Simonetti S, Cerroni L, Liso A, Falini B et al. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab

monotherapy. *Lancet Oncol.* 2004;5:64–5.

87. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. *Blood.* 2006;107:4514–23.

Book chapters

1. “Anemie”, “Emopoiesi clonale”, “Alterazioni qualitative e quantitative dei leucociti”, “Leucemia mieloide acuta” in: *Manuale di Ematologia*. A cura di P. Corradini e R. Foà. Edizioni Minerva Medica. III edizione, Torino 2020. ISBN: 978-88-7711-971-1.
2. “Mieloma Multiplo: biologia, criteri diagnostici e prognostici” in: *Seminari di Ematologia Clinica*. A cura di Alberto Bosi. Edizioni Internazionali, Pavia 2016. ISSN 2038-2839
3. “The Molecular Pathogenesis of Haematological Cancers” in: *Postgraduate Haematology*, 7a edizione. A cura di A. Victor Hoffbrand, Douglas Higgs, Atul B. Mehta, David M. Keeling. Wiley: Oxford 2015. ISBN: 9781118854327.
4. Member of the Scientific Committee of the 5th Italian edition of “Manuale Merck di diagnosi e terapia” (translated from the 18th English edition). Milano, Raffaello Cortina Editore Srl, 2008. ISBN: 9788847007079.
5. “Leucemie acute dell'Adulto” in: *Enciclopedia medica italiana UTET*. (3rd update of the 2nd edition). L. Vella editore. - Firenze: USES, 2008. - ISBN 9788802080253.

Grants awarded on a competitive basis

- | | |
|-----------|---|
| 2021-2023 | Institutional grant from the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. EUR 100'000 |
| 2019-2024 | Consolidator Grant from the European Research Commission (ERC): “spontaneous evolution and clonal heterogeneity in monoclonal gammopathies: from mechanisms of progression to clinical management – BECOMING”. EUR 1'998'7812016 e 2018 |
| 2016-2018 | My First AIRC grant from the Associazione Italiana per la Ricerca sul Cancro. EUR 188'000 |
| 2012-2014 | EHA fellowship from the European Haematology Association. EUR 72'000 |
| 2012-2013 | Starter grant for academic clinical lecturers from the Academy of Medical Sciences. GBP 30'000 |
| 2009-2011 | Leukemia and Lymphoma Society Career Development Program Special Fellow Award. USD 195'000 |
| 2007-2009 | American-Italian Cancer Foundation (AICF) International Fellowship Award. USD 70'000 |
| 2005-2007 | Federazione Italiana per la Ricerca sul Cancro (FIRC, Italian Federation for Cancer Research) Fellowship Award. EUR 45'000 |

Honors and awards

- | | |
|------|---|
| 2013 | First prize “Under 40 in Hematology – Giovani ematologi a confronto” promosso dalla Società Italiana di Ematologia. EUR 6'000 |
| 2012 | Winner of the Young Scientist Award at the 17th meeting of the European Haematology Association with an abstract titled: “Whole Exome Sequencing Defines Clonal Architecture and Genomic Evolution in Multiple Myeloma”. EUR 5000 |
| 2011 | Winner of a Lady Tata Award for a project titled: “Genetic modifiers of the phenotypic landscape in JAK2 ^{V617F} myeloproliferative neoplasms”. EUR 12'000 |
| 2006 | Winner of the “Grazia Caiani Bartocci” prize from the Accademia Anatomico-Chirurgica of the University of Perugia in Mat 2006 with |

a project titled "Aspetti funzionali delle mutazioni del gene NPM1".
EUR 4.000

Invited Lectures at national and international meetings

2021	American Society of Hematology (Atlanta, 11-14 th December)
2021	Speaker at the "Myeloma Research Workshop from bedside to bench" Parma, Italy (online, 28 th of September). "The genomics of smoldering myeloma"
2021	Chair of abstract session at the "International Myeloma Workshop" (Vienna, 8 th –11 th of September)
2021	Speaker at the virtual seminar "Multiple Myeloma: from diagnosis to the evaluation of the minimal residual disease" (online, 17 th June) "Diagnostics of the Multiple Myeloma: the biological point of view".
2021	Speaker at the 2021 meeting of the European Hematology Association (online, 9 th -17 th of June). "Genetic drivers of progression from MGUS to myeloma".
2021	Speaker at the 8th Heidelberg Myeloma Workshop (online, 17 th of April). "Genomics of early MM"
2021	Speaker at the 2nd European Myeloma Network Meeting – Amsterdam (online, 3 rd of March). "The role of the immunomicroenvironment in evolving myeloma precursor states"
2020	Speaker at the first SOHO Clinical And Biological School Of Multiple Myeloma (online, 15-17 th of December). Title of the talk: "Molecular pathogenesis of multiple myeloma".
2020	Speaker at the Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma of the 62nd meeting of the American Society of Hematology (online, 3 rd of December). Title of the talk: "Molecular/ Genomic Evolution of Multiple Myeloma".
2020	Speaker at the meeting "MultiLab: multiple round tables on Multiple Myeloma". (online, 24 th of November). Title of the talk: "clonal evolution and genomics of plasma cell dyscrasias".
2020	Tutor at the second edition of Master in management del Mieloma Multiplo by the European Myeloma Network (online, 19 th of November)
2020	2nd Society of Hematological Oncology (SOHO) Italian conference (Rome, 22nd-24 th of September). 15th session: Multiple Myeloma – MRD, Biology and near future. Title of the talk: Genetic profiling of Multiple Myeloma in novel agents era
2020	inaugural meeting on advances in myeloma precursor conditions in the 21st century (Online, 20 th of August): Session on genomics of SMM. Title of the Talk: Genomic markers using WGS
2020	Strategies of treatment of Multiple Myeloma: towards personalization of care (Brescia, 31 st of January): "genetic heterogeneity of multiple myeloma".
2020	21 st European Multiple Myeloma Academy (Wien, 23-25 January): "Molecular pathogenesis of multiple myeloma".
2019	Highlights from IMW (Bologna, 19-20 November): "Genomic profile of MGUS and smoldering MM".
2019	47° congresso della Società Italiana di Ematologia (Rome, 7-9 October): "Applicazioni cliniche della medicina di precisione in ematologia neoplastica".
2019	Corso Educazionale from bench to bedside nel mieloma multiplo (Padova, 24 September): "Minimal Residual Disease nel Mieloma Multiplo: dalla biologia alla clinica".

- 2019 What's next in multiple myeloma (Catania, 23 September): "The role of next-generation sequencing in multiple myeloma"
- 2019 Progetto Ematologia Emilia Romagna (Cesena, 21 September): "la multiclonalità delle malattie ematologiche e la loro evoluzione clonale"
- 2019 17th international myeloma workshop (Boston, 12-15 September): "Genomic Profiling: How is MGUS/SM different from Active MM?"
- 2019 24o congresso della European Haematology Association (Amsterdam, 13-16 June). "Clonal heterogeneity in Multiple Myeloma"
- 2019 Next Generation Sequencing Dal laboratorio alla pratica clinica: un percorso ad ostacoli? Terza Edizione (Milan, 3 April)
- 2018 Multiple myeloma and related malignancies (Bari 8-10 November)
- 2018 MD Anderson Cancer Center Leukemia and Lymphoma. Europe and the USA: Linking Knowledge and Practice (Dubrovnik, 5 October)
- 2018 Seminari di Aggiornamento in Ematologia Neoplastica (Rionero in Vulture, 27 September)
- 2018 SIES Discutiamone insieme: Le Sfide Della Medicina Di Precisione In Ematologia (Bologna, 28 June)
- 2018 1° Myeloma-Lab Workshop: Esperienze Ed Aggiornamenti Dai Laboratori (Miltenyi Biotech, Bologna 31 May)
- 2017 Università degli Studi di Milano, Center for Complexity & Biosystems (Milan, 14 December)
- 2017 9° Meeting Triveneto sul Mieloma e Gammopatie Monoclonali (Padova, 9-10 November)
- 2017 NGS nella pratica clinica oncologica (Cagliari, 25 May)
- 2017 Novel Insights In Biology Myeloma: The Seed And Soil (Catania, 17-18 February)
- 2016 Ospedale San Raffaele (Milan, 14 March)
- 2016 "POST-ORLANDO 2015" – Novità dal Meeting della Società Americana di Ematologia (Genova, 12 February)
- 2016 Università di Bologna, Istituto di Ematologia "L.A.Seràgnoli" (Bologna, 10 February)
- 2015 La Gestione del Paziente con Mieloma Multiplo (Milan, 23 June)
- 2015 SIES Discutiamone insieme: Basi molecolari dalla progressione neoplastica e della farmaco-resistenza nel Mieloma Multiplo (Florence, 19 March)
- 2015 Stage Mieloma Multiplo (Milan, 12 March)
- 2014 Istituto Clinico Humanitas (Milan, 7 March).
- 2014 Istituto Nazionale Tumori (Milan, 15 January).
- 2014 LLRs Trials Acceleration Programme (TAP) (London, 10 January).
- 2013 "Molecular Pathology and Diagnosis of Cancer", Wellcome Trust Advanced Course (Hinxton, 10-15 November).
- 2013 B cell malignancies: the impact of biomarkers on treatment decisions (York, 10 May).
- 2013 6th International Symposium on the Biology and Immunology of Cutaneous Lymphoma - 2nd World Congress on Cutaneous Lymphoma (Berlin, 6-9 February).

- 2012 "Molecular Pathology and Diagnosis of Cancer", Wellcome Trust Advanced Course (Hinxton, 9-14 December).
- 2009 14o congresso della European Haematology Association (Berlin, 4-7 June). "NPM1 in-focus session"

- Memberships**
- 2018-present Italian Society of Hematology – SIE (Member)
- 2016-present Italian Society of Experimental Hematology – SIES (Member)
- 2014-2016 Advisory Board of the charity "Damiano per l'ematologia"
- 2013-present Senior Member, St Edmunds College, Cambridge UK.
- 2009-2012 American Society of Hematology (Member).
- 2007-present European Hematology Association (Member).

Personal information I authorize the handling of personal information in this curriculum, according to D.Lgs n. 196/03 and following modifications and Regulations EU 679/2016 (General Regulations concerning Data Protection or GRDP)

Date 01/09/2021

Signature

